Evidence map›Paper›PMID 25614320›Full record

ReviewNature reviews. Immunology2015

Cholesterol, inflammation and innate immunity.

Alan R Tall, Laurent Yvan-Charvet

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03829046 (The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease), which is not on this map. Cited by 856 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
856citing papers in PubMed, 2 pooled it
94.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03829046 phase4completedstarted 2019, after this paper: background citation

The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)

Ran2019Enrolled41Registered outcomes11Posted comparisons0ConditionsAtherosclerotic Vascular Disease, Microvascular Dysfunction, Type2 DiabetesArmsEvolocumab, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

856 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,415 citations in OpenAlex.

  1. Review of OxLDL Driven Inflammatory Cell Activation.Current atherosclerosis reports · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Impact of Preoperative Nutrition Status on Wound Healing in Patients With Chronic Limb-Threatening Ischemia Undergoing Endovascular Therapy.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

796 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alan R TallDivision of Molecular Medicine, Department of Medicine, Columbia University, 630 West 168th Street, New York, New York 10032, USA.
Laurent Yvan-CharvetUniversity of Nice, Unité Mixte de Recherce (UMR), Institut national de la Santé et de la Recherche Médicale U1065, 062104 Nice Cedex 3, France.
Columbia University · USUniversité Côte d'Azur · FR

Funding

Cholesterol efflux, CHIP and inflammasome activationR01HL107653 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2011 to 2026
$7.7M
NHLBI NIH HHS HL107653NHLBI NIH HHS R01 HL107653
6 · The paper itself

Abstract

Hypercholesterolaemia leads to cholesterol accumulation in macrophages and other immune cells, which promotes inflammatory responses, including augmentation of Toll-like receptor (TLR) signalling, inflammasome activation, and the production of monocytes and neutrophils in the bone marrow and spleen. On a cellular level, activation of TLR signalling leads to decreased cholesterol efflux, which results in further cholesterol accumulation and the amplification of inflammatory responses. Although cholesterol accumulation through the promotion of inflammatory responses probably has beneficial effects in the response to infections, it worsens diseases that are associated with chronic metabolic inflammation, including atherosclerosis and obesity. Therapeutic interventions such as increased production or infusion of high-density lipoproteins may sever the links between cholesterol accumulation and inflammation, and have beneficial effects in patients with metabolic diseases.

Indexed as

Immunity, InnateAnimalsBiological TransportCholesterolHumansInflammationMacrophagesCholesterol

Identifiers

PMID25614320
PMCPMC4669071
OpenAlexW2033883349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.